Tel:
Fax:
Email:
Creative Biolabs
Product

NeuroMab™ Anti-PCSK9 BBB Shuttle Antibody, Clone 15.14.2

[CAT#: NRZP-1022-ZP3009]

Host Species:
Human
Species Reactivity:
Human
Applications:
ELISA; Block; Inhib; In Vitro; In Vivo

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

SPECIFIC INQUIRY

inquiry
Size:
Conjugation:
Endotoxin:
Purity:
Engineering:
Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Human

Clone Number

15.14.2

Applications

ELISA; Block; Inhib; In Vitro; In Vivo
Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only
Target

Target

PSK9

Official Name

PCSK9

Full Name

Proprotein Convertase Subtilisin/Kexin Type 9

Alternative Names

Proprotein Convertase Subtilisin/Kexin Type 9; Subtilisin/Kexin-Like Protease PC9; NARC-1; NARC1; PC9; Convertase Subtilisin/Kexin Type 9 Preproprotein; Hypercholesterolemia; Autosomal Dominant 3; Neural Apoptosis Regulated Convertase 1; Neural Apoptosis-Regulated Convertase 1;
Product Pictures
ELISA

Figure 1 is an ELISA experiment of human antibody binding to human PCSK9.

ELISA

Figure 2 represents the comparison of antibody 18.156.8 and reference antibodies 24B9.1, 12H11.1 and BMK.115 with respect to binding to human PCSK9 as determined by the ELISA method.

ELISA

Figure 3 shows the comparison results of antibody 18.156.8 and reference antibody 24B9.1, 12H11.1 and BMK.115 blocking PCSK9 and LDLR binding as determined by ELISA method.

ELISA

Figure 4 shows the ability of antibody 18.156.8 and reference antibodies 12H11.1 and BMK.115 to restore LDL uptake in HepG2 cells.

ELISA

Figure 5 shows the experimental results of anti-PCSK9 antibodies 15.14.2-uAb1-IgG4L, fully human 17.72.3-uAb1-IgG4K and 19.3.8-uAb1-IgG4L in restoring LDL uptake in hepatocellular carcinoma (HepG2) cells.

ELISA

Figure 6 shows human antibody blocking PCSK9 to be tested using the LDL-R panel ELISA.

Publications

Publications (0)

gift-card

Related Products
For Research Use Only. Not For Clinical Use.
Send Inquiry Send Inquiry
Inquiry Basket
compare

Send inquiry